Harrow Health, Inc. (HROW) Stock

Harrow Health, Inc. (HROW) is a Healthcare stock trading at $40.95 (as of 2026-08-21), with a market capitalization of $1.53B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Harrow Health, Inc. is an ophthalmic-focused healthcare company that develops and commercializes treatments in eye care through businesses that include ImprimisRx and DEXYCU. It also holds equity interests in Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals, and owns royalty rights in certain clinical-stage drug candidates.

Understand Harrow Health, Inc.: how it makes money

Harrow Health is an ophthalmic-focused healthcare company, it makes money by commercializing eye-related therapies and by owning ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business.

The profit engine is repeat use in branded ophthalmic products (tracked by reorder and refill rates) supported by an ophthalmology outsourcing and compounding platform (ImprimisRx).

Business quality (Weak): This business has operating indicators tied to repeat dispensing, but the latest quarter shows a very negative operating margin in the provided data, which is a key risk to near-term earnings power.

Bull case

  • Repeat dispensing indicators are strong: iHESO Reorder Rate is 86%, and Vivi Refill Rate is 90% (both provided).
  • Commercial expansion signals: Vivi Prescriber Base Expansion is 12% (provided).
  • Gross margin is positive in the provided quarter: Gross margin is 61.2% for the period ended 2026-03-31 (provided).

Bear case

  • Operating losses are large in the provided quarter: Operating margin is -50.0% for the period ended 2026-03-31 (provided).
  • Some payer coverage is not guaranteed: iHESO Claims Not Covered is 3.0% (provided), which can pressure sell-through and mix.
  • Portfolio includes clinical-stage equity risk: The company holds equity interests in clinical-stage programs such as Surface Ophthalmics and Melt Pharmaceuticals, which face development and commercialization uncertainty.
Valuation — source: SEC EDGAR (first-party)
Price$40.95
Market Cap$1.53B
EV / EBITDA80.3
Price / Book53.84
Price / Sales5.68
FCF Yield0.9%
DCF Value (model)$6.83
DCF Upside vs Price-83.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$272.30M
Net Margin-1.9%
Revenue Growth (YoY)-7.6%
EPS Growth (YoY)48.0%
FCF Growth (YoY)-147.1%
Financial Health — source: SEC EDGAR
Altman Z-Score3.37 (safe)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderOpaleye Management Inc. ($99.86M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark L. Baum
Employees382
CountryUS
IPO Date2007-09-28

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

  • Ligand Pharmaceuticals Incorporated (LGND)
  • Schrödinger, Inc. (SDGR)
  • Xeris Biopharma Holdings, Inc. (XERS)
  • Rigel Pharmaceuticals, Inc. (RIGL)
  • Ironwood Pharmaceuticals, Inc. (IRWD)
  • Arcus Biosciences, Inc. (RCUS)
  • Keros Therapeutics, Inc. (KROS)
  • CorMedix Inc. (CRMD)
HROW earnings history · HROW institutional & insider holders · HROW KPIs & operating metrics · HROW financials · HROW investor presentations & press releases · HROW SEC filings · HROW peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.